Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Metformin decreases the levels of Bacteroides fragilis while increasing the bile acid GUDCA to antagonize intestinal FXR and improves the metabolic health of humans and mice.
Mutationally activated BRAF-V600E influences the behavior of different types of cells in the brain and leads to promotion of seizures as well as brain tumors, indicating how both can be pharmacologically targeted in the clinic.
T cells that react to SpCas9 are observed in the peripheral blood mononuclear cells isolated from healthy humans. These findings may have implications for CRISPR–Cas9 therapeutics.
The translation initiation complex mediates tumor immune escape in melanoma by controlling STAT1 mRNA levels and T lymphocyte–induced PD-L1 expression.
Cross-sectional and longitudinal PET imaging of amyloid beta and tau in the human brain is combined with gene expression profiles to define the interactions between Alzheimer’s disease-related pathology propagation and brain-region-specific vulnerability.
A resource of preclinical pediatric brain tumor models with detailed molecular characterization provides a platform for the community to test novel therapeutic approaches.
A quantitative proteomic approach overcomes a major bottleneck in translational immunology, namely the identification of autologous and bacterial immunodominant major histocompatibility complex class II epitopes based on genomic sequences.
A reinforcement learning agent, the AI Clinician, can assist physicians by providing individualized and clinically interpretable treatment decisions to improve patient outcomes.